Bullish
Pfizer's stock hits new 52-week high amid positive developments
Pfizer's stock reached a new 52-week high of $29.09 on September 1, 2026, driven by a confidential settlement in the Depo-Provera litigation and positive analyst sentiment. The company also reported strong earnings and raised its 2026 revenue outlook, further bolstering investor confidence.
Key points
- Pfizer's stock reached a new 52-week high of $29.09 on September 1, 2026.
- Pfizer reached a confidential settlement covering over 6,000 federal lawsuits alleging that Depo-Provera was associated with intracranial meningioma.
- Analysts have raised Pfizer's fiscal 2026 EPS estimate, indicating potential earnings stabilization or improvement.
- Pfizer's oncology growth plans, including the success of Padcev and pipeline programs like PF-08634404, support long-term revenue growth.
Sources
- Pfizer (NYSE:PFE) Hits New 52-Week High - What's Next?MarketBeat · September 1, 2026
- Pfizer Reaches Confidential Settlement in Depo-Provera LitigationMarketBeat · September 1, 2026
- Pfizer FY2026 EPS Estimate Increased by Erste Group BankMarketBeat · September 1, 2026
- From Padcev to PF-08634404: Pfizer’s Oncology Growth PushMarketBeat · September 1, 2026
AI-generated from public news sources. Not financial advice.
